Stuart Essig Bio

STUART M. ESSIG, Ph.D., currently serves as managing director of his family office, Prettybrook Partners LLC, investing in medical technology companies. Prettybrook has approximately 25 active investments in a variety of companies, typically as a co-investor with institutional private equity. Dr. Essig has been Integra LifeSciences Corporation’s (NASDAQ: IART) Chairman of the Board of Directors since 2012 and a director since he joined Integra in 1997. He recently served as the company’s Executive Chairman from 2024 to mid-2025. He served as the company’s Chief Executive Officer from 1997 to 2012, building Integra into a global surgical products leader. During Stuart’s more than 28-year tenure with the company, Integra has grown revenues from approximately $15 million to over $1.6 billion and its market capitalization from approximately $100 million to an aggregate valuation of more than $3.0 billion. Before joining Integra, Dr. Essig was managing director of the medical technology practice at Goldman, Sachs & Co. He had ten years of broad healthcare experience at Goldman Sachs, serving as a senior mergers and acquisitions advisor to a broad range of domestic and international medical technology, pharmaceutical and biotechnology clients. Dr. Essig has chaired audit, compensation, finance and nominating and governance committees, served as lead director, and participated in CEO succession processes, on the boards of numerous public companies, ranging in size from several hundred million dollars to $50 billion in levered market capitalization. In addition to Integra, Dr. Essig currently serves on the Board of Directors of IDEXX Laboratories, Inc. (NASDAQ: IDXX) and on the Board of Managers of Availity, LLC, the nation’s largest real-time health information network. He is also a venture partner at Wellington Partners Advisory AG, a venture capital firm. Dr. Essig has served on the Boards of Directors of four S&P500/Fortune500 companies including St. Jude Medical Corporation (NYSE: SJM) from 1999 to 2017 prior to its sale to Abbott Corporation, Owens & Minor, Inc. (NYSE: OMI) from 2013 to 2019, Zimmer Holdings, Inc. (NYSE: ZBH) from 2005 to 2008, and IDEXX Laboratories currently. He served on the Boards of Orthofix (NASDAQ: OFIX) from 2023 to 2024, Seaspine Holdings (NASDAQ: SPNE) from 2015 to 2022 prior to its merger with Orthofix, and Vital Signs, Inc. (NASDAQ: VITL) from 1998 to 2002. He also served as Chairman of the Board of venture backed Mission Bio Inc., a life sciences business delivering single-cell multiomics solutions for precision medicine, and as Executive Chairman and Lead Director of private-equity backed Breg, Inc., a manufacturer of sports medicine products. He served as a senior advisor to TowerBrook Capital Partners, a senior advisor to Water Street Healthcare Partners, and as an executive-in-residence at Cardinal Partners. Dr. Essig was a founding investor member of Tigerlabs, a Princeton-based business accelerator. He also served on the executive committee, nominating and governance committee, and as treasurer of ADVAMED, the Advanced Medical Technology Association. Dr. Essig is also involved in several non-profit charitable organizations, including from time to time serving on their boards. He serves on the Leadership Council of the Princeton University School of Engineering and Applied Sciences. He previously served on the NACD Compensation Committee Chair Advisory Council. From 2012 to 2018, he served on the Board of Directors of Trenton-area non-profit, Isles, Inc. and from 2006 to 2024 as a volunteer and fund raiser for the Children’s Brain Tumor Foundation. Dr. Essig received an A.B. degree and graduated with magna cum laude and Phi Beta Kappa honors from the School of Public and International Affairs at Princeton University. He completed his M.B.A. and Ph.D. degrees in financial economics from the University of Chicago, Graduate School of Business. Dr. Essig resides in Austin, TX.